Literature DB >> 25885669

Coping with cancer-related cognitive dysfunction: a scoping review of the literature.

Alix Sleight1.   

Abstract

PURPOSE: Cancer-related cognitive dysfunction (CRCD) impacts memory, attention, concentration, language, multi-tasking, and organizational skills and decreases participation and quality of life for cancer survivors. The objectives of this article are: (1) to outline the neuroscience of CRCD, its risk factors, and its effect on participation; and (2) to identify and summarize the literature on rehabilitation interventions and coping techniques for CRCD in cancer survivors.
METHODS: A scoping review of articles cited in PubMed, MEDLINE, PsychINFO, and CINAHL was performed. To be included, articles must have been published in a peer-reviewed scientific journal between 1996 and 2014, written in English, and included a quantitative or qualitative non-pharmacological study of interventions and/or coping strategies for adult cancer survivors experiencing CRCD.
RESULTS: Ten articles met the inclusion criteria for final review. Six studies tested the efficacy of rehabilitation treatments on CRCD. Three involved cognitive-behavioral therapy (CBT), while three tested neuropsychological and/or cognitive training interventions. Four qualitative studies investigated coping strategies used by survivors with CRCD.
CONCLUSIONS: CBT-based treatments and neuropsychological/cognitive training methods may ameliorate symptoms of CRCD. The most commonly-reported coping strategy is utilization of assistive technology and memory aids. Further research is needed about efficacious rehabilitation techniques for this population. Implications for Rehabilitation Cancer-related cognitive dysfunction (CRCD) may impact up to 50% of cancer survivors. CRCD can significantly decrease participation and quality of life during survivorship. Cognitive-behavioral therapy (CBT) and neuropsychological/cognitive training methods may ameliorate symptoms of CRCD. The most common coping strategy reported by cancer survivors with CRCD is the use of assistive technology and memory aids.

Entities:  

Keywords:  Cancer; chemotherapy; cognitive dysfunction

Mesh:

Year:  2015        PMID: 25885669     DOI: 10.3109/09638288.2015.1038364

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  6 in total

1.  Endogenous sex hormones and memory performance in middle-aged Greek women with subjective memory complaints.

Authors:  Eleni Armeni; Michail Apostolakis; Foteini Christidi; Demetrios Rizos; George Kaparos; Konstantinos Panoulis; Areti Augoulea; Andreas Alexandrou; Evangelia Karopoulou; Ioannis Zalonis; Nikolaos Triantafyllou; Irene Lambrinoudaki
Journal:  Neurol Sci       Date:  2017-11-16       Impact factor: 3.307

2.  Toward a Broader Role for Occupational Therapy in Supportive Oncology Care.

Authors:  Alix G Sleight; Leah I Stein Duker
Journal:  Am J Occup Ther       Date:  2016 Jul-Aug

3.  Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.

Authors:  Lauren E Himmel; Maryam B Lustberg; A Courtney DeVries; Ming Poi; Ching-Shih Chen; Samuel K Kulp
Journal:  Exp Toxicol Pathol       Date:  2016-08-21

4.  Nested Cohort Study to Identify Characteristics That Predict Near-Term Disablement From Lung Cancer Brain Metastases.

Authors:  Andrea L Cheville; Jeffrey R Basford; Ian Parney; Ping Yang; Felix E Diehn
Journal:  Arch Phys Med Rehabil       Date:  2016-09-22       Impact factor: 3.966

5.  A meta-review of qualitative research on adult cancer survivors: current strengths and evidence gaps.

Authors:  Rebekah Laidsaar-Powell; Stephanie Konings; Nicole Rankin; Bogda Koczwara; Emma Kemp; Carolyn Mazariego; Phyllis Butow
Journal:  J Cancer Surviv       Date:  2019-11-19       Impact factor: 4.442

6.  Predictors of Work-Related Disability During Early Phases of Breast Cancer Treatment.

Authors:  Rachelle Brick; Elizabeth Skidmore; Lauren Terhorst; Michael McCue; Catherine Bender
Journal:  Am J Phys Med Rehabil       Date:  2019-07       Impact factor: 2.159

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.